Page 1 of 1
AACR
Posted: Tue Apr 04, 2017 5:50 pm
by biopearl
It seems reasonable to expect a PR at the conclusion of AACR (ends tomorrow) probably from Janssen summarizing all of the Janssen presentations including the Imetelstat/Venetoclax combination poster. It would be hard to allow the impressive results from this preclinical study to be left unacknowledged. Right now it is obviously under the radar. I would think the 24 week analysis in the R/R group (enrollment stopped on or before Sept 12th), should be complete by now, certainly the primary end points of symptom improvement and spleen reduction are. Other secondary end points especially molecular response will take longer to analyze but we should be hearing something conclusive relatively soon. Since the pilot study should have top line data in May (according to CT site) perhaps we will hear about both then. In any case at least for the primary end points (at the 24 week mark for all the original 9.4 patients) the data set should be in hand at Janssen by now in the R/R group. bp
Re: ASCO/2017
Posted: Tue Apr 04, 2017 10:04 pm
by jingledsassy
abstracts released may 17 for june 2nd thru 6th conf chicao ill...jmho this is when the imetelstat trial results will become public...ASCO CONF...
Re: AACR
Posted: Wed Apr 05, 2017 2:40 pm
by biopearl
jingle, agree that ASCO this year seems a likely forum for release of data but not for announcements re resumption of study enrollment (or adjustments to protocol e.g. for R/R MF study.) Once the Q2 review is complete I think some announces occur regarding the direction of the current studies and we won't have to wait for ASCO for that. bp
Re: AACR
Posted: Wed Apr 05, 2017 3:20 pm
by HOOSIER57
Hmmm.....May 17, is also the 2 year presentation of JNJ pharmaceutical division.
Re: AACR
Posted: Wed Apr 05, 2017 6:31 pm
by biopearl
Geron press release and full poster presentation available on Geron home page. bp
Re: AACR
Posted: Wed Apr 05, 2017 6:59 pm
by biopearl
This is the last line in the conclusion section of the AACR poster:
Prolonged survival was achieved in vivo when
combining imetelstat with ABT-199; four mice
remained alive ~80 days post end of treatment
suggesting a potential cure in these animals
The mouse portion of this study apparently looked at one cell line, MOLM-13 but to look at the words "potential cure" in 40 % (four) mice is certainly worthy of attention. Is anyone aware of "cure" from chemo alone in AML in animal studies anywhere? If so please share so we can compare. The Geron PR is upbeat and we shall see what the coming weeks bring. bp